The effectiveness of an epidermal growth factor containing cream on postinflammatory hyperpigmentation after 1064 nm Q-switched Nd:YAG laser treatment of Hori nevus in Asians

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210301001

Enrollment

Registered

2021-03-01

Start date

2019-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Participants with symmetrical Hori nevus Epidermal growth factor Postinflammatory hyperpigmentation 1,064-nm Q-switched Nd:YAG laser Hori nevus

Interventions

Epidermal growth factor containing cream was applied twice daily for 8 weeks,Cold cream which composed of water, pentaerythrityl tetraethylhexanoate, butylene glycol, glyceryl stearate, pentylene glyc

Active Comparator Drug,Placebo Comparator Drug

Epidermal growth factor containing cream,Cold cream

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1 Healthy participants 2 Symmetrical Hori nevus 3 Aged 18-60 years

Exclusion criteria

Exclusion criteria: 1 History of laser, light therapy for Hori nevus 2 History of topical bleaching agents or chemical peels < 4 wk 3 An active facial skin infection/inflammation 4 History of recurrent herpes infection 5 Immunocompromised host 6 Pregnancy or breast feeding

Design outcomes

Primary

Measure	Time frame
Postinflammatory hyperpigmentation at 4 and 8 weeks after intervention started melanin index	—

Secondary

Measure	Time frame
postlaser erythema at 1, 3, 7 days after intervention started erythema index,skin barrier function at 1, 3, 7 days after intervention started transepidermal water loss	—

Countries

Thailand

Contacts

Public ContactSasipaka Sindhusen

Mahidol University

S.sasipaka@gmail.com6622011141

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026